Have you wondered what makes Retatrutide different from popular GLP-1 Agonists? Unless you’ve been living under a rock, you’ve heard of semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro). But lately a new contender has stepped into the ring, retatrutide. This is Eli Lilly’s investigational triple agonist that is turning heads with even bigger numbers in clinical trials. Let’s look at the data together: How They Work: - Semaglutide: Single GLP-1 receptor agonist. Mainly suppresses appetite, slows gastric emptying, boosts insulin. - Tirzepatide: Dual GLP-1 + GIP agonist. Stronger appetite control + better insulin sensitivity. - Retatrutide: Triple agonist (GLP-1 + GIP + glucagon). Adds glucagon-mediated energy expenditure (fat burning + calorie burn boost). This unique third target is why it may outperform the others. Weight Loss Results // Mean % Body Weight Change: - Semaglutide 2.4 mg (STEP 1 trial, NEJM 2021): -14.9% at 68 weeks (vs. -2.4% placebo). About 50% of people lost ≥15%. - Tirzepatide 15 mg (SURMOUNT-1 trial, NEJM 2022): -20.9% at 72 weeks (vs. -3.1% placebo; efficacy estimand up to -22.5%). Head-to-head (SURMOUNT-5, 2025): 20.2% vs. semaglutide’s 13.7%. - Retatrutide 12 mg (Phase 2, NEJM 2023): -24.2% at just 48 weeks (vs. -2.1% placebo). At 24 weeks: up to -17.5%. 83% achieved ≥15% loss. No plateau observed. TL:DR - Retatrutide is showing faster and greater weight loss in trials, likely thanks to the glucagon component. Other Benefits & Safety: All three improve cardiometabolic markers (A1C, lipids, blood pressure). Common side effects: Gastrointestinal (nausea, diarrhea, vomiting) mostly dose-related and usually mild/moderate with proper titration across the class. Retatrutide-specific note: Dose-dependent heart rate increase (peaks ~week 24, then declines); no major cardiovascular safety signals in Phase 2/3 so far. Important: Retatrutide is not yet FDA-approved (Phase 3 TRIUMPH program ongoing/reading out). Semaglutide and tirzepatide are approved and widely available. Data sources (all peer-reviewed unless noted): - Retatrutide Phase 2: Jastreboff et al., NEJM 2023 https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 - Semaglutide STEP 1: Wilding et al., NEJM 2021 - Tirzepatide SURMOUNT-1: Jastreboff et al., NEJM 2022(CryptoDaddi)